Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:29 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 21,216 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 2 Interventional

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

NCT00001048
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
9
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 1, 2026, 10:29 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases

NCT02831348
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Cystic Fibrosis, Pneumonia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Nov 1, 2026, 10:29 AM EST
Completed Not applicable Interventional

Achieving Better Control for Older Adults With Asthma

NCT01979055
View directory record Official record
Conditions
Asthma, Elderly
Interventions
Self-regulation intervention, Telephone follow-up
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 1Phase 2 Interventional Results available

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT03309878
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
Mogamulizumab, Pembrolizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Sacramento, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 2 Interventional Results available

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

NCT01177735
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

NCT03107208
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Interventions
Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults

NCT01931176
View directory record Official record
Conditions
Dengue
Interventions
rDEN2Δ30-7169 vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Nov 1, 2026, 10:29 AM EST
Recruiting Phase 1 Interventional

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

NCT04843852
View directory record Official record
Conditions
Hepatitis B, Chronic Hepatitis B
Interventions
Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

NCT02639338
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 2 Interventional

A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir

NCT00002452
View directory record Official record
Conditions
HIV Infections
Interventions
L-756423, Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 10:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity

NCT01494649
View directory record Official record
Conditions
Dentinal Sensitivity, Hypersensitivity
Interventions
Test Toothpaste, Negative Control Toothpaste
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 2Phase 3 Interventional Results available

Autologous Transplant for Multiple Myeloma

NCT00177047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Stem Cell Transplant, Cyclophosphamide + Mesna, Melphalan, Granulocyte-colony stimulating factor
Procedure · Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01212952
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
pomalidomide, bortezomib, dexamethasone, laboratory biomarker analysis, gene expression analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Nov 1, 2026, 10:29 AM EST
Terminated Phase 1 Interventional

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

NCT02061449
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma
Interventions
Romidepsin, Poly ICLC, Focal lesional radiation
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Nov 1, 2026, 10:29 AM EST
Completed Not applicable Interventional

Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients

NCT04783038
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplant
Interventions
Distance Reiki, Sham distance Reiki
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 2 Interventional

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

NCT00036452
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
27
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 2 Interventional

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

NCT00006252
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
fludarabine phosphate, Cyclophosphamide, PBSC, G-CSF, Donor lymphocytes
Drug · Biological
Lead sponsor
Cancer and Leukemia Group B
Network
Eligibility
Up to 69 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
19
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Nov 1, 2026, 10:29 AM EST
Completed Not applicable Interventional Results available

Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma

NCT02517047
View directory record Official record
Conditions
Asthma
Interventions
CareTRx
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 3 Interventional Results available

A Study in Adults With Type 1 Diabetes

NCT01421147
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2963016, Lantus, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Hollywood, Florida • New Port Richey, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 2 Interventional

Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

NCT00342134
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Stem Cell Transplanataion
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 10:29 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

NCT05071209
View directory record Official record
Conditions
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions
Elimusertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 1, 2026, 10:29 AM EST
Completed Not applicable Interventional

Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations

NCT00002398
View directory record Official record
Conditions
HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 10:29 AM EST
Completed Phase 2 Interventional

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

NCT01067287
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT-011, Dendritic Cell Fusion Vaccine
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 1, 2026, 10:29 AM EST
Terminated Phase 2 Interventional Results available

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

NCT00505921
View directory record Official record
Conditions
Lymphoma
Interventions
Campath-1H, G-CSF, GM-CSF, BCNU, Stem Cell Transplant, Preparative Regimen for Allogenic Stem Cell Transplantation, Cytarabine, Etoposide, Melphalan, Campath, Fludarabine, Cyclophosphamide, Low dose total body irradiation
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Nov 1, 2026, 10:29 AM EST